Realizing the Promise of Revers Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report: The RPPA (Reverse Phase Protein Array) Society

Rehan Akbani*, Karl-Friedrich Becker‡, Neil Carragher§, Ted Goldstein¶, Leanne de Koning||, Ulrike Korf**, Lance Liotta‡‡, Gordon B. Mils*, Satoshi S. Nishizuka§§, Michael Pawlak§§§, Emanuel F. Petricoin III‡‡, Harvey B. Pollard¶¶, Bryan Serrels§ and Jingchun Zhu¶  
*  University of Texas M.D. Anderson Cancer Center, Huston, Texas;
‡ Technische Universität München, München, Germany;
§ Edinburgh Cancer Center Research UK Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Scotland, UK;
¶ Center for Biomelular Science and Engineering, University of California, Santa Cruz, California; ǀǀ Institu Curie, Paris, France;
** German Cancer Research Center (DKFZ), Heidelberg, Germany;
‡‡ George Mason University, Fairfax, Virginia;
§§ Iwate Medical University, Morioka, Iwate, Japan;
¶¶ Uniformed Services University of the Health Sciences, Bthesda, Maryland;
§§§ The Natural and Medical Sciences Institute, Reutlingen, Germany 


Reverse phase protein array (RPPA) technology introduced a miniaturized “antigen-down” or “dotblot” immunoassay suitable for quantifying the relative, semi-quantitative or quantitative (if a wellaccepted reference standard exists) abundance of total protein levels and post-translational modifications across a variety of biological samples including cultured cells, tissues, and body fluids. The recent evolution of RPPA combined with more sophisticated sample handling, optical detection, quality control, and better quality affinity reagents provides exquisite sensitivity and high sample throughput at a reasonable cost per sample. This facilitates large-scale multiplex analysis of multiple post-translational markers across samples from in vitro, preclinical, or clinical samples. The technical power of RPPA is stimulating the application and widespread adoption of RPPA methods within academic, clinical, and industrial research laboratories.


Parc d'activités Activestre
31390 Carbonne - FRANCE


Phone +33 561 971 974
Fax +33 561 971 975